Hormone Therapy in 2025: Safer Choices and Better Conversations
Hormone replacement therapy is entering 2025 with a more individualised focus. In Australia, the treatment is usually called menopausal hormone therapy (MHT), although many people still use the familiar term HRT. Current discussions are moving beyond a simple question of whether hormones are “good” or “bad” and towards which formulation, dose, route and timing may suit a particular person.
For people navigating perimenopause or menopause, symptoms can include hot flushes, night sweats, sleep disruption, vaginal dryness, mood changes, reduced sexual desire and difficulty concentrating. These experiences vary widely, and a treatment that is appropriate for one person may be unsuitable for another because of medical history, age, bleeding patterns or personal risk factors.
The developments attracting attention include wider use of transdermal oestrogen, more careful prescribing of progesterone, greater recognition of genitourinary symptoms, and clearer conversations about testosterone. Non-hormonal options are also becoming more relevant for people who cannot use MHT or prefer another approach.
Australians can encounter different advice through general practice, private menopause clinics, pharmacists, naturopaths and online retailers. A balanced decision depends on qualified medical assessment, reliable product information and follow-up rather than a one-size-fits-all promise.
A More Individual Approach To Menopause Care
The central shift is towards matching treatment to symptoms, health history and treatment goals. MHT can be highly effective for vasomotor symptoms such as hot flushes and night sweats, and systemic oestrogen is generally the most effective treatment for these concerns. It may also help sleep when disrupted by menopausal symptoms.
Timing and formulation matter. A younger person in early perimenopause may have irregular cycles and changing symptoms, while someone several years beyond their final menstrual period may need a different discussion about benefits and risks. The treatment plan should be reviewed as circumstances change rather than left untouched indefinitely.
For people with an intact uterus, systemic oestrogen is generally paired with a progestogen to protect the endometrium. Those who have had a hysterectomy may have different options, although the reason for the surgery and other health factors remain important. A GP with menopause experience can explain these distinctions without relying on blood tests alone.
Transdermal Oestrogen And Safer Delivery
Patches, gels and sprays deliver oestradiol through the skin, avoiding first-pass metabolism in the liver. This route is increasingly discussed when clotting risk, migraine with aura or other cardiovascular factors need careful consideration. It does not remove every risk, and suitability still depends on the individual, dose and medical history.
Oral tablets remain appropriate for some patients, but transdermal treatment can offer practical advantages, including flexible dose adjustment. Australian pharmacies may stock different brands and strengths at different times, so supply and PBS arrangements can influence the choice. Patients should avoid changing products or doses without speaking to their prescriber.
Local vaginal oestrogen is a separate option for dryness, burning, painful sex and urinary symptoms linked with genitourinary syndrome of menopause. It uses a low dose applied locally and is not intended to treat hot flushes throughout the body. Persistent bleeding, pelvic pain or new urinary symptoms require medical assessment rather than self-treatment.
Progesterone, Testosterone And Compounded Products
Micronised progesterone has received increased attention because some patients report better tolerability than with certain synthetic progestogens. Evidence continues to develop, and it should not be presented as risk-free or universally superior. The choice depends on uterine protection, bleeding response, interactions, availability and personal circumstances.
Testosterone may be considered for carefully diagnosed low sexual desire associated with menopause when other contributors have been assessed. It is not a general energy, weight-loss or anti-ageing treatment. Prescribing requires appropriate dosing and monitoring for acne, unwanted hair growth, voice changes, mood effects and changes in cholesterol or liver markers.
“Bioidentical” is an easily misunderstood term. Some regulated products contain chemically identical hormones, while custom-compounded preparations may have less consistent potency, quality control and safety evidence. Products marketed through social media or overseas websites can create extra risks, particularly when they promise hormone balance, rapid fat loss or guaranteed rejuvenation.
Comparing Common Treatment Pathways
| Treatment pathway | Common purpose | Important considerations |
|---|---|---|
| Transdermal oestradiol patch, gel or spray | Hot flushes, night sweats and broader systemic symptoms | Dose, skin application, migraine history and clotting risk require review |
| Oral oestrogen | Systemic menopausal symptom relief | May suit some people but has different liver and clotting considerations |
| Vaginal oestrogen | Dryness, painful sex and urinary discomfort | Local treatment does not usually address hot flushes |
| Oestrogen plus progesterone | Systemic treatment when the uterus is present | Progesterone choice and bleeding pattern need monitoring |
| Testosterone | Selected cases of persistent low sexual desire | Requires a clear indication, conservative dosing and follow-up |
| Non-hormonal treatment | Symptoms when MHT is unsuitable or unwanted | Options may include prescribed medicines, psychological support and lifestyle measures |
The “best” option is therefore not determined by whether a product is natural, compounded, oral or transdermal. It is determined by the clinical purpose, the evidence behind the product, the person’s risk profile and the quality of follow-up.
In Australia, treatment discussions should also account for access. Someone in Brisbane, Sydney or Melbourne may find a dedicated menopause service more easily than a person in a regional Queensland town. Telehealth can improve access, but the prescriber still needs a complete history, current medication list and a plan for reviewing symptoms and side effects.
New Non-Hormonal Options And Whole-Body Health
Non-hormonal care is becoming more sophisticated. Depending on the person, options may include certain prescription medicines, cognitive behavioural therapy for menopause symptoms, sleep treatment and practical measures such as breathable clothing, cooling strategies and reduced alcohol intake. These approaches may be particularly useful when MHT is contraindicated or unwanted.
Weight changes, fatigue and mood symptoms should not automatically be blamed on declining hormones. Thyroid disease, iron deficiency, sleep apnoea, depression, medication effects and changes in activity can produce similar complaints. A clinician may use targeted tests when indicated, but hormone panels are not a universal diagnostic answer for perimenopause.
Gut health is also part of the broader wellness conversation, although claims often run ahead of evidence. Diet quality, fibre, physical activity and regular meals support general health, while supplements should be checked for interactions and credible evidence. The relationship between digestion, inflammation and mood is explored in gut microbiome and mood, but it should not replace assessment for significant anxiety or depression.
Safety, Screening And Review
Before starting systemic MHT, a clinician will usually consider unexplained vaginal bleeding, previous breast or endometrial cancer, blood clots, stroke, liver disease, cardiovascular risk, migraines and current medicines. This does not mean every risk automatically rules out treatment; it means the decision may need specialist advice or a different approach.
Breast screening should follow Australian recommendations and individual medical advice. A new breast lump, unexplained bleeding after menopause, chest pain, sudden breathlessness, one-sided leg swelling or neurological symptoms needs prompt medical attention. These warning signs should not be attributed to “hormone adjustment”.
Follow-up is part of safe prescribing. A review may assess symptom improvement, bleeding, blood pressure, adverse effects, sexual health, sleep and whether the dose remains necessary. Routine testing of hormone levels is not always useful, especially when symptoms and clinical response provide more meaningful information.
Making Sense Of Claims In The Australian Market
Australian consumers may see advertisements for “menopause reset” programs, saliva testing, hormone pellets, detox products and compounded creams. Some services provide helpful education, while others use impressive language without explaining limitations, costs or side effects. Check whether a product is approved by the Therapeutic Goods Administration, whether the practitioner is registered with AHPRA and what follow-up is included.
The cost of care can include GP appointments, specialist consultations, prescriptions, pathology, scans and pharmacy fees. Private consultations may be expensive, while local primary care can provide a useful starting point. Pharmacists can help identify application instructions and supply issues, but they cannot replace a prescribing clinician’s assessment.
Community education can make these conversations less intimidating. At the Healthy Lifestyle Expo, visitors can hear from medical and natural health professionals, compare wellness information and explore discussions about nutrition, fitness and hormonal health. Any health claim encountered at an event should still be checked against an individual medical history.
Turning Information Into A Personal Plan
A useful appointment begins with a clear record of symptoms. Note cycle changes, hot flush frequency, sleep quality, bleeding, mood, sexual symptoms, migraines, medicines, smoking status and relevant family history. Include previous blood clots, breast conditions, cardiovascular disease and treatments tried before.
Ask what the treatment is intended to improve, how quickly results may appear, which risks apply personally, what bleeding is expected, how the prescription will be reviewed and what alternatives exist. A second opinion from a GP, gynaecologist or accredited menopause practitioner can be appropriate when the diagnosis or risk profile is complex.
Hormone therapy in 2025 is less about finding a universal “best” hormone and more about making a measured choice with regulated products, realistic goals and continuing review. The concrete next step is to book a GP appointment and take a four-week symptom and medication record to discuss whether MHT, local treatment or a non-hormonal option is appropriate.